Lipella Pharmaceuticals Inc. 8-K Report: Key Financial Insights as of January 2025
Based on the provided XML section of the financial report, here are the key extracted insights:
- Entity Information:
- Company Name: Lipella Pharmaceuticals Inc.
- CIK: 0001347242
- State of Incorporation: Delaware (DE)
- SEC File Number: 005-93847
- EIN: 20-2388040
- Address: 7800 Susquehanna St. Suite 505, Pittsburgh, PA 15208
- Contact Number: (412) 901-0315
- Report Type:
- Filing Type: 8-K (Current Report)
- Report Date:
- Filing Date: January 10, 2025
- Stock Information:
- Common Stock Par Value: $0.0001 per share
- Trading Symbol: LIPO
- Exchange: NASDAQ
- Context Information:
- Period Ending: January 10, 2025
- Measurement Units:
- Currency: USD
- Shares: Shares
- Additional Insights:
- The document is structured using XBRL, which is a standardized format for reporting financial information.
- The report appears to be an 8-K filing that typically contains important information that may affect a company's financial position or share price.
This analysis provides a snapshot of the company and its current reporting status as of the specified date.